Price
Target price
€135.00
€135.00
2.270%
-
2.270%
€149.31
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Protagonist Therapeutics Inc Stock
There is an upward development for Protagonist Therapeutics Inc compared to yesterday, with an increase of €0.000 (2.270%).
With 29 Buy predictions and not a single Sell prediction Protagonist Therapeutics Inc is an absolute favorite of our community.
As a result the target price of 149 € shows a slightly positive potential of 10.37% compared to the current price of 135.0 € for Protagonist Therapeutics Inc.
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Protagonist Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Protagonist Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Comments
Protagonist Therapeutics (PTGX) was given a new $170.00 price target by Truist Financial Corporation. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "outperform" rating reaffirmed by Wedbush.
Show more
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by Citigroup Inc. from $130.00 to $175.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PTGX provided by MarketBeat
News
Takeda Pharmaceutical Q1 Earnings Call Highlights
Takeda Pharmaceutical (NYSE:TAK) said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from
Protagonist Stock Up 120%, but One Fund Just Revealed a $170 Million Exit
Hedge fund BVF reported a full exit from Protagonist Therapeutics (NASDAQ:PTGX) in its February 17, 2026, SEC filing, selling 2,560,916 shares worth an estimated $170.12 million.
According to its
Protagonist Therapeutics Director Sells 20,000 Shares Amid Strong Stock Performance
On Feb. 6, 2026, William D. Waddill, a director at Protagonist Therapeutics (NASDAQ:PTGX), exercised his stock options and immediately sold 20,000 shares, generating a transaction value of